Ceftazidime for Gram-Negative Resistance Research

Ceftazidime is a third-generation cephalosporin valued in laboratory workflows for its strong in vitro activity against aerobic Gram-negative organisms, particularly Pseudomonas aeruginosa. Its β-lactamase stability and bactericidal cell-wall target make it useful as a challenge compound, susceptibility comparator, and selection variable in Gram-negative bacterial infection research. The compound should not, however, be treated as a universal marker of carbapenemase status or as a substitute for molecular confirmation.

The practical distinction is important in studies of multidrug-resistant Enterobacter cloacae. A ceftazidime response can describe a phenotype, while PCR, plasmid-curing, conjugation, and genotyping help explain the genetic basis and mobility of that phenotype. Used together, these methods provide more informative evidence than antibiotic growth alone.

Setup and principle overview

The Ceftazidime product supplied by APExBIO is described as a solid with a molecular weight of 546.58 and formula C22H22N6O7S2. The product information reports solubility in DMSO at concentrations of at least 21.25 mg/mL, while ethanol and water are listed as unsuitable solvents; storage at −20°C is recommended. These properties should shape plate preparation, solvent controls, and aliquoting decisions.

For a standard susceptibility workflow, prepare a concentrated DMSO stock, generate working dilutions immediately before use, and keep the final solvent concentration identical across test and vehicle-control wells. Because ceftazidime inhibits bacterial cell-wall synthesis, the most direct readouts are growth inhibition, killing kinetics, colony recovery, and changes in susceptibility after a genetic manipulation. The compound is recognized as a broad-spectrum antibiotic against Pseudomonas aeruginosa, but its activity against Staphylococcus aureus is lower than that of several earlier-generation cephalosporins. It is therefore best positioned for Gram-negative studies rather than as a general-purpose Gram-positive comparator.

In clinical literature, ceftazidime is associated with treatment of bacterial pneumonia and treatment of bacterial bronchitis caused by susceptible organisms. In a research setting, those terms should be separated from prescribing decisions: an in vitro concentration-response result does not establish clinical efficacy, and resistant clinical isolates require local biosafety, susceptibility, and treatment guidance.

Step-by-step workflow for resistance and transmission studies

1. Establish the baseline phenotype

Begin with a fresh, well-characterized isolate and record colony morphology, identity, passage number, and growth medium. Run a two-fold ceftazidime dilution series with a growth control, sterility control, and vehicle control. Report the minimum inhibitory concentration as an observed laboratory value, not as evidence of a particular β-lactamase. When studying P. aeruginosa, include a reference strain and a resistant comparator if available through an approved collection.

2. Link phenotype to genetic status

Divide the experiment into matched untreated and ceftazidime-exposed arms. Extract DNA from the same passage used for susceptibility testing and use PCR to examine the target carbapenemase or β-lactamase genes selected in the study design. If the question concerns plasmid location, do not infer location from a positive PCR alone. Pair the assay with plasmid elimination, plasmid profiling, or another validated localization method, and retain a no-treatment control to identify changes caused by handling rather than antibiotic pressure.

3. Test mobility with orthogonal controls

For conjugation or transfer experiments, use a donor-only control, recipient-only control, mixed culture without selection, and mixed culture with the planned ceftazidime selection condition. Confirm putative transconjugants by colony identity testing and target-gene PCR. A colony that grows on antibiotic-containing medium is not automatically a verified transfer event; contamination, spontaneous resistance, and mixed populations must be excluded.

4. Add a dynamic response assay

MIC testing provides an endpoint, whereas time-kill or regrowth experiments show whether a concentration produces sustained suppression. Sample at predefined intervals, plate serial dilutions, and express results as viable counts with technical replicates. If the experiment is designed to model selective pressure, compare drug-free growth with sub-MIC exposure and interpret enrichment alongside final genotype and susceptibility data.

Protocol Parameters

• Stock preparation: Dissolve ceftazidime at a suggested starting concentration of 20 mg/mL in DMSO, dispense 50–100 µL aliquots, store at −20°C or colder, and aim for no more than 1 freeze–thaw cycle.
• Broth microdilution: Use 100 µL final volume per well with a two-fold series such as 0.125–256 µg/mL, include at least 3 control conditions, and incubate for 18–24 hours at 35 ± 2°C.
• Time-kill pilot: Start at approximately 5 × 10⁵ CFU/mL in 1 mL culture volumes, test 0.5×, 1×, and 2× the measured MIC, and collect samples at 0, 2, 4, 8, and 24 hours at 35 ± 2°C.
• Selection comparison: Compare drug-free medium with 0.5× MIC and 1× MIC conditions over 18–24 hours, then verify recovered colonies by identity testing and PCR before classifying them as resistant or transferred.
• DNA workflow: Process matched untreated and exposed cultures within 24 hours of the final phenotypic readout and include a no-template PCR control in every assay run.

These are practical starting conditions for assay development, not universal breakpoints. Laboratories should validate inoculum, medium, incubation, and interpretive criteria against current CLSI or EUCAST guidance and their own organism-specific controls.

Key Innovation from the Reference Study

The reference study by Chen and colleagues used a combined variable-temperature SDS plasmid-elimination approach and PCR to examine carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae collected from eight teaching hospitals. The 2025 BMC Microbiology study analyzed 54 isolates: 46 carried detectable carbapenemase-encoding genes, 44 of those 46 demonstrated successful gene transfer in conjugation experiments, and 47 of the 54 isolates carried the mobile element ISEcp1. The investigators also identified 17 ERIC-PCR genotypes, showing that similar resistance phenotypes could occur across multiple genetic backgrounds.

The practical innovation is not simply the high detection rate. It is the decision to combine gene detection, physical plasmid manipulation, conjugation, mobile-element analysis, and strain fingerprinting. For a ceftazidime workflow, that finding supports three assay choices. First, use susceptibility testing as the front-end phenotype. Second, use plasmid-curing or localization experiments when the question is chromosome versus plasmid carriage. Third, use conjugation and genotyping when the question is transmission rather than resistance alone. This design prevents a common error: interpreting growth in ceftazidime-containing medium as proof of a transferable carbapenemase gene.

The paper reported significantly higher resistance in the carbapenemase-gene-positive group to several agents, including ceftazidime/avibactam; that combination result should not be misrepresented as a direct result for plain ceftazidime. The distinction is essential when selecting the challenge compound and writing conclusions.

Advanced applications and comparative advantages

In Pseudomonas aeruginosa infection models, ceftazidime can serve as a focused Gram-negative challenge condition. Its activity against other Pseudomonas species, including P. putida, P. alcaligenes, and P. cepacia, creates opportunities for comparative susceptibility panels, although strain-level resistance must be measured rather than assumed. For Enterobacterales, the compound can help compare baseline isolates, plasmid-cured derivatives, and verified transconjugants under identical conditions.

Its main advantage over a nonspecific growth inhibitor is interpretability: a β-lactam cell-wall challenge can be paired with MIC shifts, viable-count measurements, and genetic evidence. Its main limitation is equally important. β-lactamase resistance does not mean resistance-proof activity, and ceftazidime response cannot independently identify a carbapenemase gene, plasmid backbone, or transmission route.

For a complementary protocol discussion, see Ceftazidime in Gram-Negative Infection Research: Protocols & Insights, which extends this article’s assay-planning focus with additional workflow considerations. For the epidemiological interpretation of plasmid transfer and carbapenemase dissemination, Transmission of Carbapenemase Genes in CREC During COVID-19 provides a useful extension of the reference study’s hospital-surveillance angle.

Troubleshooting and optimization tips

Unexpected growth in all wells

Check whether the compound was fully dissolved, whether the DMSO vehicle was matched, and whether the plate received the intended concentration after dilution. Inspect the sterility and positive-growth controls separately. If the stock was repeatedly warmed, prepare a fresh aliquot rather than compensating by increasing the nominal dose.

High variation between replicates

Verify inoculum uniformity, mixing after each dilution, edge-well evaporation, and timing between plate setup and incubation. Use a consistent dispensing order and avoid comparing plates incubated on different days without an internal control. A simple pilot with three independent cultures can distinguish pipetting variation from biological heterogeneity.

Apparent resistance after plasmid curing

Do not conclude that the target gene was chromosomal from one resistant colony. Reconfirm isolate identity, repeat PCR from independent colonies, and compare the post-curing MIC with the parental isolate. The phenotype may reflect a second resistance determinant, incomplete plasmid elimination, or selection of a pre-existing subpopulation.

Low conjugation recovery

Confirm donor and recipient viability before mating, include a no-selection mixture, and verify that the selection condition separates recipient background from putative transconjugants. Excessive ceftazidime pressure can suppress recovery even when transfer occurred, whereas weak selection can increase background colonies. A small pilot spanning 0.5×, 1×, and 2× MIC is more informative than relying on one unvalidated concentration.

Why this cross-domain matters, maturity, and limitations

Hospital surveillance and bench susceptibility testing answer different questions but become more powerful when connected. The reference study establishes that carbapenemase genes can be widely distributed, mobile, and present in diverse strain backgrounds; a ceftazidime experiment can then test how a defined phenotype behaves under controlled conditions. This bridge is mature enough for comparative research, but not for replacing epidemiological confirmation with a single antibiotic readout. The strongest conclusions will triangulate phenotype, genotype, mobility, and isolate relatedness.

Future outlook

Future ceftazidime studies should move from single-isolate MIC reporting toward paired phenotype-genotype datasets. The reference findings support expanded use of matched plasmid and chromosome analyses, conjugation confirmation, mobile-element tracking, and strain-level fingerprinting. In that framework, ceftazidime remains a useful experimental pressure and comparator, while molecular assays establish whether the observed response reflects a transferable determinant, a chromosomal change, or unrelated strain variation.